cycloviolacin-o2 and Neoplasms

cycloviolacin-o2 has been researched along with Neoplasms* in 2 studies

Other Studies

2 other study(ies) available for cycloviolacin-o2 and Neoplasms

ArticleYear
The "PepSAVI-MS" Pipeline for Natural Product Bioactive Peptide Discovery.
    Analytical chemistry, 2017, 01-17, Volume: 89, Issue:2

    The recent increase in extensively drug-resistant bacterial pathogens and the associated increase of morbidity and mortality demonstrate the immediate need for new antibiotic backbones with novel mechanisms of action. Here, we report the development of the PepSAVI-MS pipeline for bioactive peptide discovery. This highly versatile platform employs mass spectrometry and statistics to identify bioactive peptide targets from complex biological samples. We validate the use of this platform through the successful identification of known bioactive peptides from a botanical species, Viola odorata. Using this pipeline, we have widened the known antimicrobial spectrum for V. odorata cyclotides, including antibacterial activity of cycloviolacin O2 against A. baumannii. We further demonstrate the broad applicability of the platform through the identification of novel anticancer activities for cycloviolacins by their cytotoxicity against ovarian, breast, and prostate cancer cell lines.

    Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Antineoplastic Agents, Phytogenic; Biological Products; Cell Line, Tumor; Cyclotides; Drug Discovery; Humans; Neoplasms; Peptide Library; Viola

2017
Cyclotides: a novel type of cytotoxic agents.
    Molecular cancer therapeutics, 2002, Volume: 1, Issue:6

    Cytotoxic activities of three naturally occurring macrocyclic peptides (cyclotides) isolated from the two violets, Viola arvensis Murr. and Viola odorata L., were investigated. A nonclonogenic fluorometric microculture assay was used to examine cytotoxicity in a panel of 10 human tumor cell lines representing defined types of cytotoxic drug resistance. Additionally, primary cultures of tumor cells from patients, and for comparison normal lymphocytes, were used to quantify cytotoxic activity. All three cyclotides, varv A, varv F, and cycloviolacin 02, exhibited strong cytotoxic activities, which varied in a dose-dependent manner. Cycloviolacin 02 was the most potent in all cell lines (IC50 0.1-0.3 microM), followed by varv A (IC50 2.7-6.35 microM) and varv F (IC50 2.6-7.4 microM), respectively. Activity profiles of the cyclotides differed significantly from those of antitumor drugs in clinical use, which may indicate a new mode of action. This, together with the exceptional chemical and biological stability of cyclotides, makes them interesting in particular for their potential as pharmacological tools and possibly as leads to antitumor agents.

    Topics: Amino Acid Sequence; Antineoplastic Agents, Phytogenic; Cell Division; Cyclotides; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Molecular Sequence Data; Neoplasms; Peptides, Cyclic; Tumor Cells, Cultured; Viola

2002